home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by UroGen Pharma Ltd.

< Previous 1 2 3 4 5 Next >

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

February 15, 2023

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

January 11, 2023

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

December 19, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

December 02, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer

December 01, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference

November 21, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma

November 14, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 10, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors

November 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

November 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers

October 11, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution

September 28, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors

September 12, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 09, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Upcoming 2022 Conferences

September 07, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

August 11, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

July 27, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at Upcoming Investor Conferences

May 18, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer

May 16, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

May 13, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

May 10, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

May 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer

March 29, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

March 21, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference

February 28, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

February 10, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

February 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

UroGen Pharma to Present at Upcoming Conferences

January 05, 2022

From UroGen Pharma Ltd.

Via Business Wire

Tickers URGN

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com